Skip to content
  • News & Events
    • Recent News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
      • Board Diversity Matrix
    • Financials
      • SEC Filings
      • Quarterly Results
      • Annual Reports
    • Stock Information
      • Stock Information
      • Analyst Coverage
    • Investor Resources
      • Email Alerts
      • Investor Contacts
  • Contact
Menu
  • News & Events
    • Recent News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
      • Board Diversity Matrix
    • Financials
      • SEC Filings
      • Quarterly Results
      • Annual Reports
    • Stock Information
      • Stock Information
      • Analyst Coverage
    • Investor Resources
      • Email Alerts
      • Investor Contacts
  • Contact
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate nelitolimod
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate nelitolimod
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Innovative Treatments for Liver & Pancreatic Tumors
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Platform
    • Drug Delivery Technology
  • Pipeline
    • Our Pipeline
    • Candidate nelitolimod
  • Clinical Trials
  • For Patients
  • About
  • News & Events
    • Recent News & Events
    • Press & Media
  • Culture
    • The Trisalus Culture
    • Careers
  • Partnering
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
      • Board Diversity Matrix
    • Financials
      • SEC Filings
      • Quarterly Results
      • Annual Reports
    • Stock Information
      • Stock Information
      • Analyst Coverage
    • Investor Resources
      • Email Alerts
      • Investor Contacts
  • Contact

Clinical Trials

At TriSalus, we are committed to advancing the treatment of liver and pancreatic tumors. Our approach has the potential to improve outcomes and enhance the quality of life for patients with these diseases.

The TriSalus™ investigational platform delivers a novel therapeutic (nelitolimod (also known as SD-101)) directly to the site of disease using a proprietary pressure-enabled infusion method. We believe this approach will stimulate the immune system, thereby enabling improved efficacy of systemic immunotherapies like checkpoint inhibitors or cell therapy.

With patients at the center of all we do and leading oncology experts driving our mission, TriSalus is conducting robust clinical trial programs to evaluate our targeted approach. Our investigators care for cancer patients each day and are driven to seek new treatment options for patients with liver and pancreatic tumors.

Information on TriSalus clinical trials in liver and pancreatic cancers, including information for healthcare providers and patients interested in participating in any ongoing clinical trials, can be found at www.clinicaltrials.gov.

Medical professionals may also email us at clinical@trisaluslifesci.com for more information about study participation.

Ongoing Clinical Trials

  • Locally-Advanced Pancreatic Ductal Adenocarcinoma
Active, not recruiting participants [ ]

Pressure-Enabled Delivery of Nelitolimod via Pancreatic Retrograde Venous Infusion with Checkpoint Blockade in Adults with Locally-Advanced Pancreatic Ductal Adenocarcinoma (PERIO™-03).

For additional information, including study sites, please visit periotrial.com.

  • Uveal Melanoma with Liver Metastases
Active, not recruiting participants [ ]

Intrahepatic Delivery of Nelitolimod by Pressure-Enabled Regional Immuno-Oncology (PERIO™-01), with Checkpoint Blockade in Adults With Metastatic Uveal Melanoma.

For additional information, including study sites, please visit periotrial.com.

  • Primary Liver Tumors: Hepatocellular Carcinoma (HCC) & Intrahepatic Cholangiocarcinoma (ICC)
Active, not recruiting participants [ ]

Pressure-Enabled Delivery of Nelitolimod with Checkpoint Blockade for Primary Liver Tumors (PERIO™-02).

For additional information, including study sites, please visit periotrial.com.

patient early access policy

What Is a Clinical Trial?

A clinical trial is a study that is conducted to evaluate the safety and effectiveness of a new therapy. Clinical trials are regulated by the FDA in the US.

clinicaltrials.gov
© 2024 TriSalus Life Sciences, Inc. All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use
Linkedin Twitter
Linkedin Twitter
© 2023 TriSalus Life Sciences, Inc.
All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use

IMPORTANT NOTICE

You are now leaving the Trisalus life Sciences corporate website.

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus’ standards.

Third Party Sites

TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.

Thank you for visiting our site.

YES
CANCEL